MarketWatch

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

The MarketWatch News Department was not involved in the creation of this content. -- ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 ...
Nasdaq

Senti Biosciences Reports Positive Preliminary Data from Phase 1 Trial of SENTI-202 in Relapsed/Refractory AML at AACR Annual Meeting 2025

Senti Bio reports promising Phase 1 results for SENTI-202 in treating relapsed/refractory AML, with positive efficacy and safety profiles. Positive preliminary data from the Phase 1 clinical trial of ...
Benzinga.com

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting. On Tuesday, the U.S. Food and Drug Administration (FDA) granted ...
Yahoo Finance

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
The Globe and Mail

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

“SENTI-202 continues to demonstrate deep, durable responses and a favorable safety profile in patients with relapsed or refractory AML, where standard therapies often offer patients a survival rate of ...